Biostem Technologies (BSEM) Expected to Announce Earnings on Thursday

Biostem Technologies (NASDAQ:BSEM) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Biostem Technologies to post earnings of ($0.43) per share and revenue of $7.17 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Biostem Technologies (NASDAQ:BSEM) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02). The company had revenue of $7.90 million for the quarter, compared to the consensus estimate of $6.35 million. Biostem Technologies had a negative return on equity of 60.22% and a negative net margin of 76.02%. On average, analysts expect Biostem Technologies to post ($1.90) EPS for the current fiscal year and ($1.04) EPS for the next fiscal year.

Biostem Technologies Stock Performance

BSEM stock opened at $1.12 on Tuesday. The stock has a market capitalization of $20.91 million, a price-to-earnings ratio of -0.70 and a beta of 0.36. Biostem Technologies has a 1 year low of $1.01 and a 1 year high of $8.40. The stock’s fifty day moving average is $2.77 and its two-hundred day moving average is $4.08.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BSEM. Weiss Ratings started coverage on shares of Biostem Technologies in a report on Wednesday, August 19th. They issued a “sell (d-)” rating on the stock. Wall Street Zen upgraded shares of Biostem Technologies to a “sell” rating in a research report on Saturday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $9.00.

Biostem Technologies Company Profile

BioStem Technologies, Inc is a biotechnology company focused on regenerative medicine and biologic tissue products. The company develops, manufactures and commercializes human tissue allografts intended to support wound care, tissue repair and other medical applications.

Its product portfolio includes placental- and birth-tissue-derived products, such as amniotic membrane and umbilical cord allografts. These products are marketed for use by healthcare providers in areas including wound management, surgical procedures and related regenerative-care applications.

BioStem Technologies serves the U.S.